1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Cancer Minimally Invasive Surgery Market
4. Market Overview
    4.1. Overview
    4.2. Market Dynamics
        4.2.1. Drivers
        4.2.2. Restraints
        4.2.3. Opportunities
    4.3. Global Prostate Cancer Minimally Invasive Surgery Market Value Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Regulatory Scenario by Region/Globally
    5.2. Key Industry Events
    5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Procedure
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Procedure, 2017–2031
        6.3.1. Laparoscopic Surgery
        6.3.2. Robotic Surgery
        6.3.3. Radiation Therapy
        6.3.4. Cryosurgery
        6.3.5. Others
    6.4. Market Attractiveness Analysis, by Procedure
7. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Stage
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Stage, 2017–2031
        7.3.1. Early-stage Prostate Cancer (Stages I and II)
        7.3.2. Locally Advanced Prostate Cancer (Stage III)
        7.3.3. Advanced Prostate Cancer (Stage IV)
    7.4. Market Attractiveness Analysis, by Stage
8. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2017–2031
        8.3.1. Hospitals
        8.3.2. Specialty Clinics
        8.3.3. Ambulatory Surgery Centers
    8.4. Market Attractiveness Analysis, by End-user
9. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Procedure, 2017–2031
        10.2.1. Laparoscopic Surgery
        10.2.2. Robotic Surgery
        10.2.3. Radiation Therapy
        10.2.4. Cryosurgery
        10.2.5. Others
    10.3. Market Value Forecast, by Stage, 2017–2031
        10.3.1. Early-stage Prostate Cancer (Stages I and II)
        10.3.2. Locally Advanced Prostate Cancer (Stage III)
        10.3.3. Advanced Prostate Cancer (Stage IV)
    10.4. Market Value Forecast, by End-user, 2017–2031
        10.4.1. Hospitals
        10.4.2. Specialty Clinics
        10.4.3. Ambulatory Surgery Centers
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Procedure
        10.6.2. By Stage
        10.6.3. By End-user
        10.6.4. By Country
11. Europe Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Procedure, 2017–2031
        11.2.1. Laparoscopic Surgery
        11.2.2. Robotic Surgery
        11.2.3. Radiation Therapy
        11.2.4. Cryosurgery
        11.2.5. Others
    11.3. Market Value Forecast, by Stage, 2017–2031
        11.3.1. Early-stage Prostate Cancer (Stages I and II)
        11.3.2. Locally Advanced Prostate Cancer (Stage III)
        11.3.3. Advanced Prostate Cancer (Stage IV)
    11.4. Market Value Forecast, by End-user, 2017–2031
        11.4.1. Hospitals
        11.4.2. Specialty Clinics
        11.4.3. Ambulatory Surgery Centers
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Procedure
        11.6.2. By Stage
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Procedure, 2017–2031
        12.2.1. Laparoscopic Surgery
        12.2.2. Robotic Surgery
        12.2.3. Radiation Therapy
        12.2.4. Cryosurgery
        12.2.5. Others
    12.3. Market Value Forecast, by Stage, 2017–2031
        12.3.1. Early-stage Prostate Cancer (Stages I and II)
        12.3.2. Locally Advanced Prostate Cancer (Stage III)
        12.3.3. Advanced Prostate Cancer (Stage IV)
    12.4. Market Value Forecast, by End-user, 2017–2031
        12.4.1. Hospitals
        12.4.2. Specialty Clinics
        12.4.3. Ambulatory Surgery Centers
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Procedure
        12.6.2. By Stage
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Procedure, 2017–2031
        13.2.1. Laparoscopic Surgery
        13.2.2. Robotic Surgery
        13.2.3. Radiation Therapy
        13.2.4. Cryosurgery
        13.2.5. Others
    13.3. Market Value Forecast, by Stage, 2017–2031
        13.3.1. Early-stage Prostate Cancer (Stages I and II)
        13.3.2. Locally Advanced Prostate Cancer (Stage III)
        13.3.3. Advanced Prostate Cancer (Stage IV)
    13.4. Market Value Forecast, by End-user, 2017–2031
        13.4.1. Hospitals
        13.4.2. Specialty Clinics
        13.4.3. Ambulatory Surgery Centers
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Procedure
        13.6.2. By Stage
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Procedure, 2017–2031
        14.2.1. Laparoscopic Surgery
        14.2.2. Robotic Surgery
        14.2.3. Radiation Therapy
        14.2.4. Cryosurgery
        14.2.5. Others
    14.3. Market Value Forecast, by Stage, 2017–2031
        14.3.1. Early-stage Prostate Cancer (Stages I and II)
        14.3.2. Locally Advanced Prostate Cancer (Stage III)
        14.3.3. Advanced Prostate Cancer (Stage IV)
    14.4. Market Value Forecast, by End-user, 2017–2031
        14.4.1. Hospitals
        14.4.2. Specialty Clinics
        14.4.3. Ambulatory Surgery Centers
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Procedure
        14.6.2. By Stage
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2021)
    15.3. Company Profiles
        15.3.1. AngioDynamics
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. B. Braun SE
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Becton, Dickinson and Company
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.)
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Intuitive Surgical
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Medtronic
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. Olympus Corporation
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Siemens Healthcare GmbH
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Teleflex Incorporated
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Product Portfolio
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
| 世界の前立腺癌低侵襲手術市場2022-2031:手術別(腹腔鏡手術、ロボット手術、放射線治療、冷凍手術、その他) | 
| 【英語タイトル】Prostate Cancer Minimally Invasive Surgery Market (Procedure: Laparoscopic Surgery, Robotic Surgery, Radiation Therapy, Cryosurgery, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 | |
|  | ・商品コード:TMR23FB111 ・発行会社(調査会社):Transparency Market Research ・発行日:2022年12月22日 ・ページ数:120 ・レポート言語:英語 ・レポート形式:PDF ・納品方法:Eメール(受注後24時間以内) ・調査対象地域:グローバル ・産業分野:医療 | 
| Single User(1名様閲覧) | USD5,795 ⇒換算¥869,250 | 見積依頼/購入/質問フォーム | 
| Multi User(5名様閲覧) | USD8,795 ⇒換算¥1,319,250 | 見積依頼/購入/質問フォーム | 
| Corporate License(法人閲覧) | USD11,795 ⇒換算¥1,769,250 | 見積依頼/購入/質問フォーム | 
| ※販売価格オプションの説明 ※お支払金額:換算金額(日本円)+消費税 ※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡) ※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能) | 
| Transparency Market Research社の当調査資料では、2022年に27億ドルであった世界の前立腺癌低侵襲手術市場規模が2031年には39億ドルまで達し、予測期間中に年平均3.6%成長すると予測しています。本調査資料では、前立腺癌低侵襲手術の世界市場について広く調査・分析しています。本書は、序論、仮定・調査方法、エグゼクティブサマリー、市場概要、主要インサイト、手術別(腹腔鏡手術、ロボット手術、放射線治療、冷凍手術、その他)分析、ステージ別(早期前立腺癌(ステージI・II)、局所進行性前立腺癌(ステージIII)、進行性前立腺癌(ステージIV))分析、エンドユーザー別(病院、専門クリニック、外来手術センター)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などを整理しています。なお、当市場の主要企業には、AngioDynamics、B. Braun SE、Becton, Dickinson and Company、Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.)、Intuitive Surgical、Medtronic、Olympus Corporation、Siemens Healthcare GmbH、Teleflex Incorporatedなどが含まれています。 ・序論 ・仮定・調査方法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の前立腺癌低侵襲手術市場規模:手術別 - 腹腔鏡手術の市場規模 - ロボット手術の市場規模 - 放射線治療の市場規模 - 冷凍手術の市場規模 - その他の市場規模 ・世界の前立腺癌低侵襲手術市場規模:ステージ別 - 早期前立腺癌(ステージI・II)における市場規模 - 局所進行性前立腺癌(ステージIII)における市場規模 - 進行性前立腺癌(ステージIV)における市場規模 ・世界の前立腺癌低侵襲手術市場規模:エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - 外来手術センターにおける市場規模 ・世界の前立腺癌低侵襲手術市場規模:地域別 - 北米の前立腺癌低侵襲手術市場規模 - ヨーロッパの前立腺癌低侵襲手術市場規模 - アジア太平洋の前立腺癌低侵襲手術市場規模 - 中南米の前立腺癌低侵襲手術市場規模 - 中東・アフリカの前立腺癌低侵襲手術市場規模 ・競争状況 | 
Prostate Cancer Minimally Invasive Surgery Market – Scope of Report
TMR’s report on the global prostate cancer minimally invasive surgery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global prostate cancer minimally invasive surgery market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global prostate cancer minimally invasive surgery market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the prostate cancer minimally invasive surgery market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global prostate cancer minimally invasive surgery market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global prostate cancer minimally invasive surgery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global prostate cancer minimally invasive surgery market.
The report delves into the competitive landscape of the global prostate cancer minimally invasive surgery market. Key players operating in the global prostate cancer minimally invasive surgery market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global prostate cancer minimally invasive surgery market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market prostate cancer minimally invasive surgery.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
 WorldWideScience.org
 Elsevier, Inc.
 National Institutes of Health (NIH)
 PubMed
 NCBI
 Department of Health Care Service
Trade Data Sources
 Trade Map
 UN Comtrade
 Trade Atlas
Company Information
 OneSource Business Browser
 Hoover’s
 Factiva
 Bloomberg
Mergers & Acquisitions
 Thomson Mergers & Acquisitions
 MergerStat
 Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖
| ★調査レポート[世界の前立腺癌低侵襲手術市場2022-2031:手術別(腹腔鏡手術、ロボット手術、放射線治療、冷凍手術、その他)] (コード:TMR23FB111)販売に関する免責事項を必ずご確認ください。 | 
| ★調査レポート[世界の前立腺癌低侵襲手術市場2022-2031:手術別(腹腔鏡手術、ロボット手術、放射線治療、冷凍手術、その他)]についてメールでお問い合わせ | 
 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			